<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927654</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002090-12</org_study_id>
    <nct_id>NCT00927654</nct_id>
  </id_info>
  <brief_title>Iloprost in High Risk Cardiac Surgical Patients</brief_title>
  <acronym>Ilocard</acronym>
  <official_title>Effect of Iloprost Inhalation Before and During Extracorporeal Circulation (ECC) on Perioperative Morbidity and Outcome in High Risk Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algora</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis)&#xD;
      before and during extracorporal circulation on perioperative morbidity and outcome in high&#xD;
      risk cardiac surgical patients is investigated in comparison to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of post-operative artificial respiration after arrival on intensive care unit</measure>
    <time_frame>2-3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>90 days lethality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Iloprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Sodium Chloride solution 0.9 %</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost (Ventavis)</intervention_name>
    <description>Twice 20 µg at day 0 (total dose 40 µg) intraoperatively</description>
    <arm_group_label>Iloprost</arm_group_label>
    <other_name>Ventavis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Sodium Chloride solution 0.9 % (placebo)</intervention_name>
    <description>Twice at day 0 intraoperatively</description>
    <arm_group_label>Isotonic Sodium Chloride solution 0.9 %</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  for females of childbearing potential: negative pregnancy test&#xD;
&#xD;
          -  patients, male or female, 18 to 85 years old&#xD;
&#xD;
          -  elective open-heart surgery using heart-lung-machine&#xD;
&#xD;
          -  patients with increased risk to suffer from perioperative right heart failure, i.e.,&#xD;
&#xD;
               -  protracted surgery: multiple valvular transplant or expected bypass time&#xD;
                  exceeding 120 min and/or&#xD;
&#xD;
               -  patients with preoperative known pulmonary hypertension and/or&#xD;
&#xD;
               -  patients with severe heart insufficiency (NYHA III or NYHA IV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient not able to give consent&#xD;
&#xD;
          -  pregnant or nursing patients&#xD;
&#xD;
          -  Anamnestic known hypersensitivity to the used drug (Ventavis) and its ingredients or&#xD;
             to drugs with a similar chemical structure&#xD;
&#xD;
          -  blood clotting disorder requiring treatment&#xD;
&#xD;
          -  trauma, intracerebral bleeding or apoplexy within the last 3 months prior to surgery&#xD;
&#xD;
          -  primary or secondary immune deficiency (e.g., pretreatment with steroids, cytostatics)&#xD;
&#xD;
          -  systemic infection&#xD;
&#xD;
          -  lung disorder with impaired gas exchange&#xD;
&#xD;
          -  lung transplantation&#xD;
&#xD;
          -  cardiac transplantation&#xD;
&#xD;
          -  implantation of LVAD (left ventricular assist device)&#xD;
&#xD;
          -  fluoride ulcus disorder&#xD;
&#xD;
          -  planned surgery in deep hypothermia and cardiac arrest&#xD;
&#xD;
          -  subconscious and psychiatric disordered patients&#xD;
&#xD;
          -  participation in another clinical trial within the last 30 days prior to study start&#xD;
             and up to 30 days after end of study&#xD;
&#xD;
          -  previous participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Zwissler, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the university of Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the university of Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the university of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the university of munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. B. Zwissler</investigator_full_name>
    <investigator_title>Director Clinic for Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Iloprost</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>cardio pulmonary morbidity</keyword>
  <keyword>high risk cardiac surgical patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

